Literature DB >> 20164289

Pseudotumor cerebri after surgical remission of Cushing's disease.

Erin N Kiehna1, Meg Keil, Maya Lodish, Constantine Stratakis, Edward H Oldfield.   

Abstract

CONTEXT: Pseudotumor cerebri has only been described after successful surgery for Cushing's disease (CD) in case reports. We sought to establish the incidence and timing of its occurrence, identify predisposing factors, characterize the clinical presentations and their severity, and examine the effects of treatment in patients who underwent surgery for CD.
SETTING: This study was conducted at two tertiary care centers: The University of Virginia and the National Institutes of Health. PATIENTS: We conducted a retrospective review of 941 surgeries for CD (723 adults, 218 children) to identify patients who developed pseudotumor cerebri after surgery for CD and examine the associated clinical features.
RESULTS: Seven children (four males, three females; 3%), but no adults, developed pseudotumor cerebri postoperatively. All underwent resection of an ACTH-secreting adenoma, and postoperative serum cortisol reached a nadir of less than 2 microg/dl. After surgery, all were placed on tapering hydrocortisone replacement therapy. Within 3-52 wk, all seven patients experienced symptoms of pseudotumor cerebri and had ophthalmological examination demonstrating papilledema. One patient had diplopia from a unilateral VIth nerve palsy. Six patients were still on steroid replacement at onset of symptoms. In three patients, a lumbar puncture demonstrated elevated opening pressure. Four patients were treated successfully with a lumbar puncture, steroids, and/or Diamox. Three patients did not receive treatment, and their symptoms resolved over several months. There was no correlation between the degree of hypercortisolism (24-h urinary free cortisol) before surgery and the likelihood of developing pseudotumor cerebri after surgery (P < 0.23).
CONCLUSIONS: This series demonstrates a 3% occurrence of pseudotumor cerebri in children after successful surgery for CD, but the absence of the syndrome in adults. Pseudotumor cerebri manifests itself within 1 yr of surgery, often while patients are still undergoing replacement steroid therapy. A patient exhibiting signs of intracranial hypertension after surgery for CD should undergo an evaluation for pseudotumor cerebri. Recognition of the symptoms and treatment should correct and/or prevent ophthalmological sequelae.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164289      PMCID: PMC2853987          DOI: 10.1210/jc.2009-2449

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Pediatric pseudotumor cerebri: descriptive epidemiology.

Authors:  K Gordon
Journal:  Can J Neurol Sci       Date:  1997-08       Impact factor: 2.104

Review 2.  Idiopathic intracranial hypertension.

Authors:  M Wall
Journal:  Neurol Clin       Date:  1991-02       Impact factor: 3.806

3.  Experimental effects of steroids and steroid withdrawal on cerebrospinal fluid absorption.

Authors:  I Johnston; D L Gilday; E B Hendrick
Journal:  J Neurosurg       Date:  1975-06       Impact factor: 5.115

Review 4.  Reduced C.S.F. absorption syndrome. Reappraisal of benign intracranial hypertension and related conditions.

Authors:  I Johnston
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

5.  The effect of dexamethasone phosphate on the production rate of cerebrospinal fluid in the spinal subarachnoid space of dogs.

Authors:  O Sato; M Hara; T Asai; R Tsugane; N Kageyama
Journal:  J Neurosurg       Date:  1973-10       Impact factor: 5.115

6.  Benign intracranial hypertension after pituitary surgery for Cushing's disease.

Authors:  V J Parfitt; J C Dearlove; D Savage; H B Griffith; M Hartog
Journal:  Postgrad Med J       Date:  1994-02       Impact factor: 2.401

7.  Pseudotumor cerebri following removal of an adrenocorticotropic hormone-secreting pituitary adenoma.

Authors:  E G Fischer; C S Anast
Journal:  Neurosurgery       Date:  1982-02       Impact factor: 4.654

Review 8.  Pseudotumor cerebri in patients with Cushing's disease.

Authors:  Michael R Rickels; Charles W Nichols
Journal:  Endocr Pract       Date:  2004 Nov-Dec       Impact factor: 3.443

9.  Development of pseudotumor cerebri after the removal of an adrenocorticotropic hormone-secreting pituitary adenoma: case report.

Authors:  N A Martin; J Linfoot; C B Wilson
Journal:  Neurosurgery       Date:  1981-06       Impact factor: 4.654

10.  Idiopathic intracranial hypertension in children: the Iowa experience.

Authors:  P Babikian; J Corbett; W Bell
Journal:  J Child Neurol       Date:  1994-04       Impact factor: 1.987

View more
  10 in total

1.  Intracranial hypertension following intrathecal administration of liposomal cytarabine.

Authors:  S Lunskens; L Lammertijn; D Deeren; B Bergmans; J Maertens; R Vandenberghe
Journal:  J Neurol       Date:  2010-08-13       Impact factor: 4.849

2.  Presumed Pseudotumor Cerebri Syndrome After Withdrawal of Inhaled Glucocorticoids.

Authors:  Young Joon Kwon; Julian L Allen; Grant T Liu; Shana E McCormack
Journal:  Pediatrics       Date:  2016-05-17       Impact factor: 7.124

Review 3.  Pediatric Pseudotumor Cerebri Syndrome: Diagnosis, Classification, and Underlying Pathophysiology.

Authors:  Claire A Sheldon; Grace L Paley; Shannon J Beres; Shana E McCormack; Grant T Liu
Journal:  Semin Pediatr Neurol       Date:  2017-04-07       Impact factor: 1.636

Review 4.  An integrated mechanism of pediatric pseudotumor cerebri syndrome: evidence of bioenergetic and hormonal regulation of cerebrospinal fluid dynamics.

Authors:  Claire A Sheldon; Young Joon Kwon; Grant T Liu; Shana E McCormack
Journal:  Pediatr Res       Date:  2014-11-24       Impact factor: 3.756

5.  Outcome of surgical treatment of 200 children with Cushing's disease.

Authors:  Russell R Lonser; Joshua J Wind; Lynnette K Nieman; Robert J Weil; Hetty L DeVroom; Edward H Oldfield
Journal:  J Clin Endocrinol Metab       Date:  2013-01-31       Impact factor: 5.958

Review 6.  Management of hormone-secreting pituitary adenomas.

Authors:  Gautam U Mehta; Russell R Lonser
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

Review 7.  Quality of life and other outcomes in children treated for Cushing syndrome.

Authors:  Margaret F Keil
Journal:  J Clin Endocrinol Metab       Date:  2013-05-02       Impact factor: 5.958

8.  Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth.

Authors:  Yakun Yang; Miaomiao Sheng; Fengming Huang; Dechao Bu; Xiaohai Liu; Yong Yao; Congxin Dai; Bowen Sun; Jindong Zhu; Yonghui Jiao; Zhenqing Wei; Huijuan Zhu; Lin Lu; Yi Zhao; Chengyu Jiang; Renzhi Wang
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

9.  Approach to Chronic Secondary Headache: A Case Report on Unusual Drug Side Effects.

Authors:  Hamid Reza Riasi; Forod Salehi; Morteza Hajihosseini
Journal:  Iran J Med Sci       Date:  2017-11

10.  Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis.

Authors:  Renzhi Wang; Yakun Yang; Miaomiao Sheng; Dechao Bu; Fengming Huang; Xiaohai Liu; Cuiqi Zhou; Congxin Dai; Bowen Sun; Jindong Zhu; Yi Qiao; Yong Yao; Huijuan Zhu; Lin Lu; Hui Pan; Ming Feng; Kan Deng; Bing Xing; Wei Lian; Yi Zhao; Chengyu Jiang
Journal:  Int J Mol Sci       Date:  2016-09-29       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.